One-Year Follow-Up Result of TARGET I Clinical Endpoint Appraisal Committee Conference Held in Beijing

Shanghai, June 25, 2012--MicroPort Scientific Corporation announced that the primary endpoint results from prospective, multicenter, randomized clinical trials for assessing the safety and effacy of Firehawk has be evaluated in the committee conference held in Beijing. Committee president, Professor Yong Huo, and other two committee members, Professor Weimin Wang and Professor Gao Wei, were invited. After analyzing data of endpoint results, including Major Adverse Cardiac Events (MACE) and related angiographic results, three professors made a rigorous, independent and authoritative appraisement and discussion, and the result will be submitted to related committee department for further data processing and analysis.